Publication | Closed Access

Intravenous treatment with human recombinant ApoA-I Milano reduces beta amyloid cerebral deposition in the APP23-transgenic mouse model of Alzheimer's disease

Neurodegenerative DiseasesAlzheimer's DiseaseIntravenous TreatmentMedicineApp23-transgenic Mouse ModelDegenerative PathologyNeurochemical BiomarkersProtein MisfoldingNeurologyNeuroscienceNeurodegenerationPharmacology